{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:36:35Z","timestamp":1794015395004,"version":"4.8.0"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Lessons Learned<\/jats:title>\n                  <jats:p>This is the first human interventional study in patients with Cowden syndrome that is driven by inactivation of germline PTEN gene. Single-agent sirolimus, a mTOR inhibitor, suppressed mTOR signaling in surrogate human tissues without significant toxicity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cowden syndrome is characterized by inactivating germline PTEN mutations, which can lead to activation of the PI3K-Akt-mTOR pathway.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult subjects with germline PTEN mutation who met international diagnostic criteria for Cowden syndrome and who had Eastern Cooperative Oncology Group (ECOG) performance status 0\u20132 and adequate organ function were enrolled. Subjects were treated with a 56-day course of daily oral sirolimus. In addition to symptom assessment and physical examination, dermatologic, endoscopic, neurologic (cerebellar), and radiographic assessments were conducted. Inhibition of the mTOR pathway in benign skin and gastrointestinal (GI) lesion was assessed by immunohistochemistry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 18 patients and 16 families were enrolled. PTEN mutations were located at exons 1\u20138. Regression of skin and GI lesions was observed by dermoscopy or endoscopy. Neurological evaluation showed improvement in cerebellar function score at 1 month. Immunohistochemistry (IHC) analysis in skin and GI benign lesions showed a decrease in the ratio of phosphorylated (p)S6 to total S6 in response to sirolimus. Ratios of pS6K to total S6 at days 14 and 56 were significantly lower than at baseline (p = .0026, p = .00391, respectively). A 56-day course of sirolimus was well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>A 56-day course of sirolimus was well tolerated in subjects with Cowden syndrome and was associated with some evidence of improvement in symptoms, skin and GI lesions, cerebellar function, and decreased mTOR signaling.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0514","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T18:59:01Z","timestamp":1564167541000},"page":"1510-e1265","source":"Crossref","is-referenced-by-count":66,"title":["A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in <i>PTEN<\/i>"],"prefix":"10.1093","volume":"24","author":[{"given":"Takefumi","family":"Komiya","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"Parkview Cancer Institute, Wayne, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Blumenthal","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"DeChowdhury","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Fioravanti","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Ballas","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"GlaxoSmithKline, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morris","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"University of Cincinnati, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Hornyak","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"VA Medical Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Wank","sequence":"additional","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Hewitt","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Morrow","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan M.","family":"Memmott","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip A.","family":"Dennis","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA"},{"name":"AstraZeneca, Gaithersburg, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"2021122508135402900_onco13056-bib-0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ymeth.2014.10.011","article-title":"PTEN hamartoma tumor syndrome: Clinical risk assessment and management protocol","volume":"77","author":"Ngeow","year":"2015","journal-title":"Methods"},{"key":"2021122508135402900_onco13056-bib-0002","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1086\/323703","article-title":"Germline mutations in BMPR1A\/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes","volume":"69","author":"Zhou","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2021122508135402900_onco13056-bib-0003","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122508135402900_onco13056-bib-0004","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/jmg.2004.018036","article-title":"Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumor syndrome","volume":"41","author":"Pilarski","year":"2004","journal-title":"J Med Genet"},{"key":"2021122508135402900_onco13056-bib-0005","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ajhg.2010.11.013","article-title":"A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands","volume":"88","author":"Tan","year":"2011","journal-title":"Am J Hum Genet"},{"key":"2021122508135402900_onco13056-bib-0006","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122508135402900_onco13056-bib-0007","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(14)70489-9","article-title":"Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study","volume":"15","author":"Franz","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0514","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0514","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1510\/41918690\/oncolo_24_12_1510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/12\/1510\/41918690\/oncolo_24_12_1510.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T08:14:53Z","timestamp":1640420093000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/12\/1510\/6439517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":7,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,7,26]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0514","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,1]]},"published":{"date-parts":[[2019,7,26]]}}}